Sign In to Request a Protocol
Sign In to Request a Protocol

CJC-1295 DAC (2 mg) + Ipamorelin (5 mg) Stack

  • Table of Contents

CJC-1295 DAC + Ipamorelin Product Information Guide

CJC-1295 DAC is dosed at 1 mg–2 mg weekly via subcutaneous injection in educational protocols. A 2 mg reconstituted with bacteriostatic water yields about 1.0 mg/mL. This information is for research and educational use only.

  • CJC-1295 DAC: Add 2.0 mL bacteriostatic water → 1.0 mg/mL; inject once weekly.
  • Ipamorelin: Add 3.0 mL bacteriostatic water → 1.67 mg/mL; inject once daily.
  • Easy measuring: CJC-1295 DAC: 1 unit = 10 mcg; Ipamorelin: 1 unit ≈ 16.7 mcg on U-100 syringes.
  • Storage: Lyophilized: ≤−15 °C (5 °F); reconstituted: 2–8 °C (35.6–46.4 °F); use within 3–4 weeks.
This product information is provided for general educational and research reference only. CJC-1295 DAC and Ipamorelin are included here as part of a general product information guide. This content is not intended as medical advice, treatment guidance, dosage guidance, or usage instruction. For product-specific details, availability, or additional information, please contact us on Telegram.
  • Product Information Guide

General educational reference for CJC-1295 DAC + Ipamorelin product information

CJC-1295 DAC Product Information

Product Overview: This information is provided for general educational and research reference only. CJC-1295 DAC is included here as part of a general product information guide.
PhaseWeekly DoseUnits (mL) per InjectionFrequency
Standard1000 mcg (1.0 mg)100 units (1.0 mL)Once weekly
Aggressive2000 mcg (2.0 mg)100 units × 2 injections (2.0 mL total)Once weekly (split)

Note: For the 2 mg weekly dose, split into two 100-unit injections on the same day or consecutive days, as a single injection would exceed 1 mL.

CJC-1295 DAC Product Information Notes

  • 1. Review the product label or packaging for basic product information.
  • 2. For product-specific details, please contact us on Telegram.
  • 3. For preparation-related information, please contact us directly.
  • 4. This content is provided for general educational and research reference only.

Ipamorelin Product Information

Reconstitution: 3.0 mL bacteriostatic water → 1.67 mg/mL (1666.7 mcg/mL) → 16.67 mcg per unit

PhaseDaily DoseUnits (mL) per InjectionFrequency
Weeks 1–2 (Initiation)100 mcg6 units (0.06 mL)Once daily
Weeks 3–4 (Titration)150 mcg9 units (0.09 mL)Once daily
Weeks 5+ (Maintenance)200 mcg12 units (0.12 mL)Once daily
Aggressive (Optional)300 mcg18 units (0.18 mL)Once daily or split 2×/day

For ≤10-unit (≤0.10 mL) administrations, consider 30- or 50-unit insulin syringes for improved readability.

Ipamorelin Reconstitution Steps

  • 1. Draw 3.0 mL bacteriostatic water with a sterile syringe.
  • 2. Inject slowly down the vial wall; avoid foaming.
  • 3. Gently swirl/roll until dissolved (do not shake).
  • 4. Label with date and refrigerate at 2–8 °C (35.6–46.4 °F).

Combined Stack Schedule — Standard Approach

Reconstitution: 3.0 mL bacteriostatic water → 1.67 mg/mL (1666.7 mcg/mL) → 16.67 mcg per unit

WeekCJC-1295 DAC (Weekly)Ipamorelin (Daily)
Weeks 1–21000 mcg (100 units) once weekly100 mcg (6 units) once daily
Weeks 3–41000 mcg (100 units) once weekly150 mcg (9 units) once daily
Weeks 5–121000 mcg (100 units) once weekly200 mcg (12 units) once daily
Timing: CJC-1295 DAC is typically administered on a fixed day each week. Ipamorelin is commonly administered before bed to coincide with natural nocturnal GH pulses.

Important: This guide is for educational purposes only and is not medical advice. For research use only. Not for human consumption.

  • Product Information
This section is provided for general educational and research reference only. For product-specific details, preparation information, or availability, please contact us on Telegram.
  • CJC-1295 DAC Vials (2 mg each):
  • 8 weeks ≈ 4 vials (1 vial = 2 weekly doses at 1 mg)
  • 12 weeks ≈ 6 vials
  • 16 weeks ≈ 8 vials
  • Ipamorelin Vials (5 mg each):
  • 8 weeks ≈ 3 vials (1 vial ≈ 25 days at 200 mcg/day)
  • 12 weeks ≈ 4 vials
  • 16 weeks ≈ 5 vials
  • Insulin Syringes (U-100):
  • Per week: 1 (CJC) + 7 (Ipamorelin) = 8 syringes
  • 8 weeks: 64 syringes
  • 12 weeks: 96 syringes
  • 16 weeks: 128 syringes
For Ipamorelin doses ≤10 units, 30- or 50-unit syringes improve accuracy.
  • Bacteriostatic Water (10 mL bottles):
  • 8 weeks: CJC (4 × 2 mL) + Ipam (3 × 3 mL) = 17 mL → 2 × 10 mL bottles
  • 12 weeks: CJC (6 × 2 mL) + Ipam (4 × 3 mL) = 24 mL → 3 × 10 mL bottles
  • 16 weeks: CJC (8 × 2 mL) + Ipam (5 × 3 mL) = 31 mL → 4 × 10 mL bottles
  • Alcohol Swabs:

Per week: ~16 swabs (2/day for Ipamorelin + 2 for CJC weekly)

  • 8 weeks: 128 swabs → 2 × 100-count boxes
  • 12 weeks: 192 swabs → 2 × 100-count boxes
  • 16 weeks: 256 swabs → 3 × 100-count boxes
  • Protocol Overview

Concise summary of general product information for educational and research reference only.

  • Product Details: This product information is provided for general educational reference only.
  • Research Reference: This content is not intended as medical advice, treatment guidance, dosage guidance, or usage instruction.
  • Availability: For product-specific details or availability, please contact us on Telegram.
  • Storage: Please follow the product label or packaging instructions for proper storage.
  • Dosing Protocol

Suggested approach for the stacked regimen.

  • CJC-1295 DAC: For product-specific details, please contact us on Telegram.
  • Ipamorelin: For availability or additional product information, please contact us on Telegram.
  • Support: Preparation-related or product-specific information is available upon request.
  • Important: This content is not intended as medical advice, dosage guidance, treatment guidance, or usage instruction.
  • Storage Instructions

Proper storage preserves peptide integrity and efficacy.

  • Product Label: Please follow the product label or packaging instructions for proper storage.
  • Product-Specific Details: For storage-related or preparation-related information, please contact us on Telegram.
  • Handling Note: Keep product information and handling details consistent with the product label.
  • Important: This content is not intended as medical advice, dosage guidance, treatment guidance, or usage instruction.
  • Important Notes

Practical considerations for consistency and safety.

  • Product Details: For product-specific details, please contact us on Telegram.
  • Preparation Information: For preparation-related information, please contact us directly.
  • Availability: Product availability information is available upon request.
  • Important: This content is not intended as medical advice, dosage guidance, treatment guidance, usage instruction, or treatment recommendation.
  • How This Works
This section provides general product information about CJC-1295 DAC and Ipamorelin for educational and research reference only. The content is intended to help visitors understand the product category in a simple and organized way. This information should not be considered medical advice, treatment guidance, dosage guidance, or usage instruction. For product-specific details, availability, or additional information, please contact us on Telegram.
  • Potential Benefits & Side Effects

Observations from preclinical and clinical literature on GH secretagogues.

  • Body composition: GH secretagogues have demonstrated improvements in lean mass and reductions in fat mass in clinical studies.
  • Sustained GH/IGF-1 elevation: CJC-1295 DAC produces prolonged elevations lasting 6–11 days per administration.
  • Selectivity: Ipamorelin does not significantly increase cortisol or ACTH at therapeutic doses.
  • Tolerability: Both peptides were well tolerated in human studies, with transient injection-site reactions being the most common adverse effect.
  • Water retention, mild headache, and transient numbness/tingling have been reported with GH-elevating compounds.
  • Lifestyle Factors

Complementary strategies for optimal outcomes.

  • Pair with a balanced, protein-forward diet tailored to individual energy and recovery needs.
  • Combine resistance training and aerobic activity to support anabolic adaptations.
  • Prioritize 7–9 hours of quality sleep; GH secretion is commonly associated with deep sleep.
  • Manage stress and avoid chronic caloric restriction, which can blunt GH response.
  • Injection Technique

General product handling information for educational and research reference only.

  • Product Handling: Please follow the product label or packaging instructions for general handling information.
  • Product-Specific Details: For product-specific details, please contact us on Telegram.
  • Preparation Information: For preparation-related information, please contact us directly.
  • Important: This content is not intended as medical advice, dosage guidance, treatment guidance, injection guidance, or usage instruction.
  • Recommended Source
We recommend Vitality Labs for product-specific information and availability.

Why Vitality Labs?

  • High-quality product information and support.
  • Clear product details available upon request.
  • For more information, please contact us on Telegram.
Contact on Telegram
  • Important Note

This content is intended for therapeutic educational purposes only and does not constitute medical advice, diagnosis, or treatment.

  • References

Journal of Clinical Endocrinology & Metabolism

— Prolonged stimulation of GH and IGF-I secretion by CJC-1295 in healthy adults
More Info

European Journal of Endocrinology

— Ipamorelin, the first selective growth hormone secretagogue
More Info

Endocrine Reviews

— Growth hormone secretagogues: mechanisms and clinical applications
More Info

Sleep Medicine Reviews

— Sleep and the GH/IGF-1 axis: physiological and clinical implications
More Info

Bachem

— Handling and storage guidelines for peptides (lyophilized stability)

More Info

Bachem

— Reconstituted peptide storage and stability recommendations
More Info

Translational Andrology and Urology (PMC)

— GH secretagogues in body composition management for hypogonadal males
More Info

International Journal of Surgery (PubMed)

— Ipamorelin for postoperative ileus: tolerability and safety in bowel resection patients
More Info

NCBI Bookshelf

— Parenteral medication administration: subcutaneous injection technique
More Info

CDC

— Vaccine administration guidelines: subcutaneous route (no aspiration required)
More Info

Growth Hormone & IGF Research (ScienceDirect)

— Ipamorelin induces longitudinal bone growth in rats
More Info

Physiological Reviews

— The somatotropic axis: GH and IGF-1 regulation and actions
More Info

Clinical Drug Investigation (PMC)

— Subcutaneous drug delivery: pharmacokinetic considerations
More Info

NCBI Bookshelf

— Best practices for injection (asepsis, preparation, and administration)
More Info

Contact on Telegram Peptides

— BPC-157 + TB-500 (10 mg blend) product page (quality and batch documentation)
More Info